Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.6K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting DNA interstrand crosslinks repair with synthetic lethality in High-Grade B-Cell Lymphoma.

Leukemia·2026
Same author

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience.

British journal of haematology·2026
Same author

Therapeutic inhibition of telomeric DNA damage response rescues hematopoietic dysfunction driven by telomere shortening and aging.

Nature aging·2026
Same author

ZEB1 integrates stemness, differentiation blockade and immune suppression to orchestrate osteosarcoma aggressiveness.

Journal of experimental & clinical cancer research : CR·2026
Same author

Clonal hematopoiesis dynamics influences long-term outcomes of follicular lymphoma: Results from FIL FOLL12 trial.

HemaSphere·2026
Same author

Failure of a LHRH agonist in metastatic prostate cancer: a case report and review of literature.

Cancer chemotherapy and pharmacology·2026

Related Experiment Video

Updated: Nov 10, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.4K

Predictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas.

Stefano A Pileri1, Claudio Tripodo2,3, Federica Melle1

  • 1Division of Haematopathology, European Institute of Oncology, IEO IRCCS, Via Ripamonti 435, 20141 Milan, Italy.

Cells
|April 3, 2021
PubMed
Summary

Molecular studies are advancing the understanding of Diffuse Large B-cell Lymphoma (DLBCL), identifying prognostic factors for tailored, potentially chemotherapy-free treatments. This research aims to improve patient outcomes with reduced toxicity.

Keywords:
classificationdiagnosisdiffuse large B-cell lymphomagene expression profilingnext-generation sequencingprognosistherapy

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.2K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.0K

Related Experiment Videos

Last Updated: Nov 10, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.4K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.2K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.0K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Diffuse Large B-cell Lymphoma (DLBCL) is the most common lymphoid malignancy globally.
  • DLBCL classification includes a common "not otherwise specified" (NOS) form and rare variants, some linked to viral agents.
  • DLBCL-NOS constitutes over 80% of DLBCL neoplasms and has been extensively studied molecularly.

Purpose of the Study:

  • To review molecular advancements in Diffuse Large B-cell Lymphoma (DLBCL).
  • To compare gene expression profiling and next-generation sequencing findings in DLBCL.
  • To highlight the potential of molecular insights for personalized DLBCL therapies.

Main Methods:

  • Review of molecular studies focusing on gene expression profiling (neoplastic cells and microenvironment).
  • Analysis of next-generation sequencing data in DLBCL.
  • Comparison of molecular findings to identify prognostic and predictive factors.

Main Results:

  • Molecular studies have identified key prognostic and predictive factors in DLBCL.
  • Gene expression profiling and next-generation sequencing offer complementary insights into DLBCL biology.
  • Integration of molecular attributes is crucial for advancing DLBCL treatment strategies.

Conclusions:

  • Amalgamation of molecular attributes is essential for achieving tailored therapies in DLBCL.
  • The long-term goal is to develop chemotherapy-free protocols for DLBCL.
  • Personalized treatment approaches aim to cure most DLBCL patients with minimal toxicity.